Literature DB >> 10606856

Late development of antidesmoglein 1 antibodies in pemphigus vulgaris: correlation with disease progression.

S Miyagawa1, M Amagai, T Iida, Y Yamamoto, T Nishikawa, T Shirai.   

Abstract

The coexistence of antidesmoglein 3 (Dsg3) and antidesmoglein 1 (Dsg1) autoantibodies is well described in patients with pemphigus vulgaris (PV); however, there is little evidence of sequential development of these two autoantibodies. Autoantibody responses to Dsg3 and Dsg1 were studied in seven PV patients over time by enzyme-linked immunosorbent assay, using baculovirus expressed recombinant fusion proteins. All patients had anti-Dsg3 IgG antibodies at presentation. Two patients developed anti-Dsg1 later in the course of the disease. The transition in autoantibody profile was associated with disease progression to generalized PV involving mucous membranes and skin in both patients; one patient initially presented with a predominantly mucosal phenotype, the other with herpetiform pemphigus-like features. These findings demonstrate that there is an extension of autoimmune response from anti-Dsg3 only to both anti-Dsg3 and anti-Dsg1 in some patients, which is associated with an alteration in clinical expression in PV.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10606856     DOI: 10.1046/j.1365-2133.1999.03209.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  17 in total

1.  p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris.

Authors:  Xuming Mao; Yasuyo Sano; Jin Mo Park; Aimee S Payne
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

2.  Clonal analysis of B-cell response in pemphigus course: toward more effective therapies.

Authors:  Giovanni Di Zenzo; Giovanna Zambruno
Journal:  J Invest Dermatol       Date:  2015-03       Impact factor: 8.551

3.  Biphasic activation of p38MAPK suggests that apoptosis is a downstream event in pemphigus acantholysis.

Authors:  Hua En Lee; Paula Berkowitz; Puneet S Jolly; Luis A Diaz; Michael P Chua; David S Rubenstein
Journal:  J Biol Chem       Date:  2009-03-07       Impact factor: 5.157

4.  Immunohistological analysis of immune cells in blistering skin lesions.

Authors:  Mahmoud R Hussein; Fayed Mahammad Nagy Ali; Abd-Elhady M M Omar
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

Review 5.  Genetics and Omics Analysis of Autoimmune Skin Blistering Diseases.

Authors:  Michael Olbrich; Axel Künstner; Mareike Witte; Hauke Busch; Anke Fähnrich
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

6.  Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display.

Authors:  Aimee S Payne; Ken Ishii; Stephen Kacir; Chenyan Lin; Hong Li; Yasushi Hanakawa; Kazuyuki Tsunoda; Masayuki Amagai; John R Stanley; Don L Siegel
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 7.  Effects of acute and chronic inflammation on B-cell development and differentiation.

Authors:  Derek Cain; Motonari Kondo; Huaiyong Chen; Garnett Kelsoe
Journal:  J Invest Dermatol       Date:  2009-02       Impact factor: 8.551

8.  Autoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skin.

Authors:  Paula Berkowitz; Michael Chua; Zhi Liu; Luis A Diaz; David S Rubenstein
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

9.  Apoptotic pathways in pemphigus.

Authors:  Meryem Bektas; Puneet Jolly; David S Rubenstein
Journal:  Dermatol Res Pract       Date:  2010-06-15

10.  Imaging and force spectroscopy on desmoglein 1 using atomic force microscopy reveal multivalent Ca(2+)-dependent, low-affinity trans-interaction.

Authors:  Jens Waschke; Carlos Menendez-Castro; Paola Bruggeman; Rainer Koob; Masayuki Amagai; Hermann J Gruber; Detlev Drenckhahn; Werner Baumgartner
Journal:  J Membr Biol       Date:  2007-07-27       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.